Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) SVP Sells 10,000 Shares of Stock

Key Points

• Oruka Therapeutics SVP Arjun Agarwal sold 10,000 shares for approximately $1.07 million under a pre-arranged Rule 10b5-1 plan, reducing his position by 39.5% to 15,312 shares.
• ORKA shares rose to $111.04, near their 52-week high of $111.37, while the company reported a quarterly loss of $0.55 per share—$0.04 worse than analyst expectations.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $134.30; institutional investors own 56.44% of the stock.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 10,000 shares of the stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total value of $1,066,600.00. Following the sale, the senior vice president owned 15,312 shares in the company, valued at approximately $1,633,177.92. This trade represents a 39.51% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, July 13th, Arjun Agarwal sold 9,999 shares of Oruka Therapeutics stock. The stock was sold at an average price of $84.63, for a total value of $846,215.37.
• On Monday, June 22nd, Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock. The stock was sold at an average price of $80.95, for a total value of $128,467.65.
• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total value of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

Oruka Therapeutics stock traded up $2.92 during midday trading on Friday, reaching $111.04. 1,047,380 shares of the company were exchanged, compared to its average volume of 1,138,555. The firm's 50-day simple moving average is $86.50 and its 200-day simple moving average is $62.27. Oruka Therapeutics, Inc. has a 1 year low of $14.08 and a 1 year high of $111.37. The company has a market capitalization of $7.35 billion, a price-to-earnings ratio of -54.70 and a beta of -0.34.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.04). On average, analysts forecast that Oruka Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ORKA. Guggenheim restated a "buy" rating and set a $200.00 target price on shares of Oruka Therapeutics in a research report on Tuesday. Weiss Ratings upgraded Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a report on Wednesday, July 15th. BTIG Research reissued a "buy" rating and set a $151.00 price target on shares of Oruka Therapeutics in a research note on Tuesday. Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $180.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, June 2nd. Ten research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $134.30.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in Oruka Therapeutics during the second quarter worth approximately $474,916,000. Viking Global Investors LP acquired a new position in shares of Oruka Therapeutics in the 3rd quarter valued at $51,280,000. Deep Track Capital LP grew its stake in shares of Oruka Therapeutics by 38.4% during the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock valued at $51,051,000 after buying an additional 735,983 shares during the period. Vanguard Group Inc. increased its holdings in shares of Oruka Therapeutics by 38.1% during the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company's stock worth $74,366,000 after buying an additional 676,865 shares during the last quarter. Finally, RTW Investments LP increased its holdings in shares of Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock worth $62,382,000 after buying an additional 112,499 shares during the last quarter. 56.44% of the stock is currently owned by hedge funds and other institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source